贝凡洛尔

化合物

贝凡洛尔INN:Bevantolol)是一种治疗心绞痛高血压的候选药物,可作为β受体阻滞剂钙通道阻滞剂[1][2]它是由华纳-兰伯特发现和开发的,[3]但在1989年1月,该公司宣布已撤回新药申请;公司董事长说:“谁需要第30个β受体阻滞剂?”[4]截至2016年,它没有在美国英国欧洲上市,考科蓝评论的作者找不到它的产品专论。[5]

贝凡洛尔
临床资料
AHFS/Drugs.com国际药品名称
给药途径口服
ATC码
识别信息
  • (RS)-[2-(3,4-dimethoxyphenyl)ethyl][2-hydroxy-3-(3-methylphenoxy)propyl]amine
CAS号59170-23-9  checkY
PubChem CID
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard英语CompTox Chemicals Dashboard (EPA)
化学信息
化学式C20H27NO4
摩尔质量345.44 g·mol−1
3D模型(JSmol英语JSmol
手性外消旋混合物
  • O(c1ccc(cc1OC)CCNCC(O)COc2cc(ccc2)C)C
  • InChI=1S/C20H27NO4/c1-15-5-4-6-18(11-15)25-14-17(22)13-21-10-9-16-7-8-19(23-2)20(12-16)24-3/h4-8,11-12,17,21-22H,9-10,13-14H2,1-3H3 checkY
  • Key:HXLAFSUPPDYFEO-UHFFFAOYSA-N checkY

参考资料

  1. ^ Frishman WH, Goldberg RJ, Benfield P. Bevantolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. Drugs. January 1988, 35 (1): 1–21. PMID 2894292. doi:10.2165/00003495-198835010-00001. 
  2. ^ Vaughan Williams EM. Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions. Journal of Clinical Pharmacology. July 1987, 27 (7): 450–60. PMID 2888789. S2CID 72749127. doi:10.1002/j.1552-4604.1987.tb03049.x. 
  3. ^ McPherson EM. Pharmaceutical Manufacturing Encyclopedia. 3rd. Burlington: Elsevier. 2007: 618–619. ISBN 9780815518563. 
  4. ^ Warner-Lambert Pipeline Narrowed to 40 Active Research Compounds. Pink Sheet. 30 January 1989 [2023-04-08]. (原始内容存档于2016-11-27). 
  5. ^ Wong GW, Boyda HN, Wright JM. Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension. The Cochrane Database of Systematic Reviews. March 2016, 3 (4): CD007451. PMC 6486283 . PMID 26961574. doi:10.1002/14651858.CD007451.pub2.